Bloomberg Law’s combination of innovative analytics, research tools and practical guidance provides you with everything you need to be a successful litigator.
Hoffmann-LaRoche Inc. must plan a new defense for 2,076 injury suits by Accutane users that were incorrectly dismissed by a New Jersey judge, a state appeals court ruled ( In re Accutane Litig. , 2017 BL 262267, N.J. Super. Ct. App. Div., No. A-4698-14T1, 7/28/17 ).
Roche told Bloomberg BNA July 31 it will ask the New Jersey Supreme Court to “take up this crucial issue, which has the potential to impact a broad range of lawsuits involving important public health issues.”
The multicounty product liability cases were restored because the trial judge in 2015 improperly barred two plaintiffs’ experts from testifying that ingestion of the acne drug caused the plaintiffs’ Crohn’s disease, the New Jersey Superior Court’s Appellate Division ruled July 28.
Crohn’s disease is a form of inflammatory bowel disease.
The reinstatement of statistician David Madigan and gastroenterologist Arthur Kornbluth is a blow to drug makers Hoffmann-LaRoche and Roche Labs, which hoped to be done with the suits but must now prepare for a trial.
Roche said it was disappointed that the appellate court is allowing the plaintiffs’ experts to “offer opinions that disregard this science, opinions which they themselves have only offered in lawsuits.”
“The medical and scientific communities have demonstrated that there is no link between Accutane and Crohn’s disease,” Roche said.
But the New Jersey appeals court said the trial court went beyond its “gatekeeping function” in determining the weight and credibility of the experts’ testimony, and in ruling the witnesses didn’t rely on scientific methodology.
The testimony, which mostly relied on observational studies, “should not have been barred because their analyses emphasized different evidence and produced different conclusions than those reached by the defense experts,” Judge Susan L. Reisner said.
The trial judge also said the experts were “hired guns” and were “on a mission” with their testimony.
The three-judge appeals panel said the trial judge’s “extreme negative reaction to plaintiffs’ witnesses” was not supported by the trial record.
The admissibility process is designed to “weed out `junk science,’ not to shield jurors from hearing expert testimony that is scientifically-based but unpersuasive to the trial judge, ” the appeals court said.
The ruling comes on the heels of an unpublished July 25 decision by a different appellate panel in the same court that reinstated 335 cases by plaintiffs who used Accutane after April 10, 2002, and alleged the drug caused ulcerative colitis, another form of inflammatory bowel disease.
A jury must decide if the post-2002 warnings, which said the drug was “associated with inflammatory bowel disease,” were adequate, the appeals court said.
But the appeals court affirmed judgment for Roche in suits by 197 plaintiffs from California, Colorado, Indiana, Maryland, Mississippi, New York, Texas, and Virginia. Under the law of those states, the warning was sufficient, it said (In re Accutane Litig., No. A-4760-14T1, 2017 BL 256585 (N.J. Super. Ct. App. Div. July 25, 2017).
Plaintiffs’ attorneys include Seeger Weiss; Lite, DePalma, Greenberg; and Weitz & Luxenberg. Defense attorneys include Covington & Burling, and Dughi Hewit & Domalewski.
To contact the reporter on this story: Bruce Kaufman in Washington at email@example.com
To contact the editor responsible for this story: Steven Patrick at firstname.lastname@example.org
Text at http://src.bna.com/reI
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)